Osivax Is A Clinical Stage Biopharmaceutical Company Based In Lyonfrancewith Additional Locations In Lia Gebelgiumand Australiafounded In 2017 As A Spin Off From Imaxioosivax Specializes In Developing Universal Vaccines Aimed At Highly Mutating Respiratory Virusesthe Company Utilizes Its Proprietary Oligodoma C Self Assembling Nanoparticle Platformwhich Effectively Targets Both T Cell And B Cell Immune Responses To Offer Broad Spectrum Protection Against Various Viral Strains The Company S Lead Candidateovx836Is A Universal Influenza Vaccine Currently In Phase 2 Trialshaving Been Tested In Over 1 200 Subjectsosivax Is Also Working Towards A Pan Respiratory Vaccine That Aims To Protect Against All Influenza Strains And Covid 19 Variants In A Single Shotthe Company Has Established Strategic Partnerships In Infectious Disease Research And Has Secured Funding To Support Its Vaccine Development Efforts
No conferences found for this company.
| Company Name | Osivax Sas |
| Country |
France
|
| Address | N/A |
| Telephone | N/A |
| N/A |
